Current Report Filing (8-k)
June 14 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 13, 2019
CELLECTAR
BIOSCIENCES, INC.
(
Exact name of registrant as specified in charter
)
|
Delaware
|
1-36598
|
04-3321804
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
100 Campus Drive, Florham Park, New Jersey
07932
(
Address of principal executive offices, and zip code
)
(608) 441-8120
(
Registrant's telephone number, including area code
)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common stock, par value $0.00001
Warrant to purchase common stock, expiring
August 20, 2019
Warrant to purchase common stock, expiring
April 20, 2021
|
|
CLRB
CLRBW
CLRBZ
|
|
NASDAQ Capital Market
NASDAQ Capital Market
NASDAQ Capital Market
|
|
ITEM 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
|
(e) Amendment and Restatement of 2015 Stock Incentive Plan
As described in Item 5.07 below, on June 13, 2019 at the 2019
Annual Meeting of Stockholders (the “Meeting”) of Cellectar Biosciences, Inc. (the “Company”), the Company’s
stockholders approved an amendment and restatement to the Amended and Restated 2015 Stock Incentive Plan (the “Plan”)
in order to increase the number of shares reserved for issuance under the plan by 700,000 shares.
A summary of the Plan is set forth in the Company’s definitive
proxy statement filed with the Securities and Exchange Commission on April 29, 2019. That summary and the above description of
the Plan do not purport to be complete and are qualified in their entirety by reference to the Plan, which is filed as Exhibit
10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|
ITEM 5.07
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
The Company convened the Meeting at 10.00 a.m., local time,
on June 13, 2019. The Meeting was held at the Executive Center on the first floor at 100 Campus Drive, Florham Park, New Jersey
07932, pursuant to notice duly given.
At the close of business on April 18, 2019, the record date
for the determination of stockholders entitled to vote at the Meeting, there were 5,102,709 shares of the Company’s Common
Stock, each share being entitled to vote, constituting all of the outstanding voting securities of the Company.
At the Meeting, the holders of 4,259,769 shares of the Company’s
Common Stock were represented in person or by proxy constituting a quorum.
Four proposals were presented for stockholder approval at the
Meeting:
Proposal No.1 – Election of Directors
Class II directors, James V. Caruso and Frederick W. Driscoll,
were nominated and elected to serve three-year terms. The vote was as follows:
|
Nominee
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
|
James V. Caruso
|
|
|
1,158,966
|
|
|
|
351,907
|
|
|
|
2,748,896
|
|
|
Frederick W. Driscoll
|
|
|
1,134,126
|
|
|
|
376,747
|
|
|
|
2,748,896
|
|
Proposal No. 2 – Approval of an Increase in the 2015
Stock Incentive Plan Shares of 700,000
We requested approval of an increase in the number of shares
of common stock available for issuance under the Amended and Restated 2015 Stock Incentive Plan by 700,000 shares. The stockholders
approved the increase
.
The vote was as follows:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
1,014,604
|
491,488
|
4,781
|
2,748,896
|
Proposal No. 3 – Approval of Executive Compensation
We requested approval on a non-binding advisory basis of the
compensation of the Company’s named executive officers. The stockholders approved the compensation. The vote was as follows:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
1,083,272
|
417,079
|
10,522
|
2,748,896
|
Proposal No. 4 – Ratification of Appointment of Independent
Registered Public Accounting Firm
We requested ratification of the appointment by the Audit Committee
of our Board of Directors of Baker Tilly Virchow Krause, LLP to be our independent registered public accounting firm for fiscal
2019. The stockholders ratified the appointment. The vote was as follows:
|
For
|
Against
|
Abstain
|
|
4,079,083
|
167,526
|
13,160
|
|
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: June 14, 2019
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Charles T. Bernhardt
|
|
|
|
Name: Charles T. Bernhardt
|
|
|
|
Title: Interim Chief Financial Officer
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2023 to Apr 2024
